ArticleNature communications2025

Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial.

Funda Meric-Bernstam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.